Drug intelligence / Profile preview

RCM-AcChoR

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes

Overview

RCM-AcChoR is a denatured preparation of the acetylcholine receptor (AcChoR) from Torpedo californica, specifically modified by complete reduction and carboxymethylation in 6 M guanidine hydrochloride. It functions as a specific immunosuppressant for experimental autoimmune myasthenia gravis (EAMG). The drug induces antibodies that react with both RCM-AcChoR and intact AcChoR, but these antibodies are non-pathogenic and have a different specificity compared to disease-inducing anti-AcChoR antibodies. This cross-reactivity and non-pathogenicity are crucial for its therapeutic effect, allowing it to prevent the onset and reverse the clinical symptoms of EAMG by modulating the immune response.

Other names: reduced carboxymethylated receptor

Targets

AChR (Acetylcholine receptor)

Beyond the preview

Go deeper on RCM-AcChoR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RCM-AcChoR.

Explore the full profile